Venus Remedies Receives Uk Market Authorization For Bleomycin 15 000 Iu

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Venus Remedies receives UK Market Authorization for Bleomycin 15,000 IU

ri-calendar-2-lineOct 26, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Venus Remedies is delighted to announce the attainment of market authorization for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion in the United Kingdom. This significant milestone, achieved through its German subsidiary Venus Pharma GmbH, not only expands the pharmaceutical giant's global footprint but also underscores its commitment to advancing cancer care through innovative solutions.

 

Bleomycin 15,000 IU is a potent medication containing the active ingredient bleomycin sulfate, belonging to the class of cytostatic drugs specifically designed to combat cancer. Renowned for its effectiveness in targeting cancer cells and preventing uncontrolled division, it finds versatile applications in treating various types of carcinomas and lymph node cancers.

 

Venus Remedies holds an impressive 15 Market Authorizations (MAs) for Bleomycin products worldwide, reflecting its dedication to making this vital treatment more accessible. The company has further submitted sixteen additional applications to Ministries of Health around the globe. This latest accomplishment reaffirms Venus's mission to enhance healthcare solutions and underscores its commitment to bringing relief to patients in need.

 

For Venus Pharma GmbH, receiving market authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK is a significant validation of its dedication to pharmaceutical excellence. This achievement enhances the company's reputation globally, signifying its competence in delivering pharmaceutical products that positively impact patient lives. Ashutosh Jain, CEO of Venus Pharma GmbH, expressed that obtaining market authorization from MHRA is a momentous accomplishment that allows the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions